​

Bioventus (BVS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BVS Stock Forecast

Bioventus (BVS) stock forecast, based on 6 Wall Street analysts, predicts a 12-month average price target of $13.00, with a high of $13.00 and a low of $13.00. This represents a 46.07% increase from the last price of $8.90.

$3 $5 $7 $9 $11 $13 $14 High: $13 Avg: $13 Low: $13 Last Closed Price: $8.9

BVS Stock Rating

Bioventus stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (66.67%), 2 Hold (33.33%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 2 4 0 Strong Sell Sell Hold Buy Strong Buy

BVS Price Target Upside V Benchmarks

TypeNameUpside
StockBioventus46.07%
SectorHealthcare Stocks 15.45%
IndustryMedical Device Stocks28.52%

Price Target Trends

1M3M12M
# Anlaysts-12
Avg Price Target-$13.00$14.00
Last Closing Price$8.90$8.90$8.90
Upside/Downside-46.07%57.30%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 2613---4
Feb, 26-3---3
Jan, 26-3---3
Dec, 25-3---3
Nov, 25-3---3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 09, 2026Barrington$13.00$8.5152.76%46.07%
May 07, 2025Chase KnickerbockerCraig-Hallum$15.00$6.20141.94%68.54%
Oct 01, 2024Caitlin CroninCanaccord Genuity$12.00$11.791.78%34.83%
Aug 07, 2024Chase KnickerbockerCraig-Hallum$12.00$8.2545.45%34.83%
May 07, 2024William PlovanicCanaccord Genuity$8.00$5.1256.25%-10.11%
Mar 13, 2024Alex NowakCraig-Hallum$9.00$5.2970.13%1.12%
Nov 30, 2022Goldman Sachs$2.50$1.9130.89%-71.91%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 06, 2026Craig-HallumBuyBuyhold
May 07, 2025Craig-HallumBuyBuyhold
Dec 02, 2024RBC CapitalOutperformupgrade
Oct 01, 2024Canaccord GenuityBuyBuyhold
Sep 27, 2024Craig-HallumBuyBuyhold
Aug 07, 2024Craig-HallumBuyBuyhold
May 07, 2024Canaccord GenuityBuyBuyhold
Dec 07, 2023Canaccord GenuityBuyupgrade
Nov 30, 2022Goldman SachsNeutralNeutralhold
Nov 22, 2022Craig-HallumHolddowngrade

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$-0.15$-2.59$-2.49$-0.52$0.34-
Avg Forecast$0.90$0.26$-0.30$0.40$0.56$0.78
High Forecast$0.90$0.26$-0.29$0.42$0.59$1.13
Low Forecast$0.90$0.25$-0.31$0.39$0.55$0.43
Surprise %-116.67%-1096.15%730.00%-230.00%-39.29%-

Revenue Forecast

$400M $450M $500M $550M $600M $650M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$430.90M$512.12M$512.35M$573.28M$568.09M-
Avg Forecast$430.39M$521.72M$500.90M$564.94M$570.79M$607.84M
High Forecast$431.54M$528.07M$517.14M$583.25M$589.29M$607.92M
Low Forecast$428.64M$510.79M$492.67M$555.66M$561.41M$607.76M
Surprise %0.12%-1.84%2.29%1.48%-0.47%-

Net Income Forecast

$-200M $-140M $-80M $-20M $40M $100M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26
Reported$19.38M$-158.70M$-156.23M$-33.54M$22.73M-
Avg Forecast$56.44M$16.13M$-19.03M$25.45M$35.76M$48.87M
High Forecast$56.64M$16.39M$-18.43M$26.25M$36.88M$70.80M
Low Forecast$56.14M$15.69M$-19.62M$24.65M$34.63M$26.93M
Surprise %-65.67%-1083.80%721.18%-231.79%-36.42%-

BVS Forecast FAQ

Is Bioventus stock a buy?

Bioventus stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Bioventus is a favorable investment for most analysts.

What is Bioventus's price target?

Bioventus's price target, set by 6 Wall Street analysts, averages $13 over the next 12 months. The price target range spans from $13 at the low end to $13 at the high end, suggesting a potential 46.07% change from the previous closing price of $8.9.

How does Bioventus stock forecast compare to its benchmarks?

Bioventus's stock forecast shows a 46.07% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the medical device stocks industry (28.52%).

What is the breakdown of analyst ratings for Bioventus over the past three months?

  • March 2026: 25.00% Strong Buy, 75.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 0% Strong Buy, 100.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Bioventus’s EPS forecast?

Bioventus's average annual EPS forecast for its fiscal year ending in December 2026 is $0.78, marking a 129.41% increase from the reported $0.34 in 2025..

What is Bioventus’s revenue forecast?

Bioventus's average annual revenue forecast for its fiscal year ending in December 2026 is $607.84M, reflecting a 7.00% increase from the reported $568.09M in 2025.

What is Bioventus’s net income forecast?

Bioventus's net income forecast for the fiscal year ending in December 2026 stands at $48.87M, representing an 114.96% increase from the reported $22.73M in 2025.